These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34955824)

  • 21. Antibiotic Exposure Profiles in Trials Comparing Intensity of Continuous Renal Replacement Therapy.
    Jang SM; Pai MP; Shaw AR; Mueller BA
    Crit Care Med; 2019 Nov; 47(11):e863-e871. PubMed ID: 31397714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing the Use of Beta-Lactam Antibiotics in Clinical Practice: A Test of Time.
    Tilanus A; Drusano G
    Open Forum Infect Dis; 2023 Jul; 10(7):ofad305. PubMed ID: 37416756
    [TBL] [Abstract][Full Text] [Related]  

  • 23. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
    Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
    Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simultaneous determination of nine β-lactam antibiotics in human plasma by an ultrafast hydrophilic-interaction chromatography-tandem mass spectrometry.
    Abdulla A; Bahmany S; Wijma RA; van der Nagel BCH; Koch BCP
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Aug; 1060():138-143. PubMed ID: 28618388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beta-Lactam Dose Optimisation in the Intensive Care Unit: Targets, Therapeutic Drug Monitoring and Toxicity.
    Legg A; Carmichael S; Chai MG; Roberts JA; Cotta MO
    Antibiotics (Basel); 2023 May; 12(5):. PubMed ID: 37237773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Why We May Need Higher Doses of Beta-Lactam Antibiotics: Introducing the 'Maximum Tolerable Dose'.
    Dhaese SAM; Hoste EA; De Waele JJ
    Antibiotics (Basel); 2022 Jul; 11(7):. PubMed ID: 35884143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A guide to therapeutic drug monitoring of β-lactam antibiotics.
    Fratoni AJ; Nicolau DP; Kuti JL
    Pharmacotherapy; 2021 Feb; 41(2):220-233. PubMed ID: 33480024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?
    Wong G; Briscoe S; Adnan S; McWhinney B; Ungerer J; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6165-70. PubMed ID: 24080664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of β-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy.
    Economou CJP; Wong G; McWhinney B; Ungerer JPJ; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2017 May; 49(5):589-594. PubMed ID: 28341612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High target attainment for β-lactam antibiotics in intensive care unit patients when actual minimum inhibitory concentrations are applied.
    Woksepp H; Hällgren A; Borgström S; Kullberg F; Wimmerstedt A; Oscarsson A; Nordlund P; Lindholm ML; Bonnedahl J; Brudin L; Carlsson B; Schön T
    Eur J Clin Microbiol Infect Dis; 2017 Mar; 36(3):553-563. PubMed ID: 27815778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Utilization of cefepime therapeutic drug monitoring in febrile neutropenia patients with hematologic malignancies.
    Lodl EF; Alshaer MH; Adams CB; Richards A; Peloquin C; Venugopalan V
    J Oncol Pharm Pract; 2023 Nov; ():10781552231213883. PubMed ID: 37981806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Right Dose Right Now: bedside data-driven personalized antibiotic dosing in severe sepsis and septic shock - rationale and design of a multicenter randomized controlled superiority trial.
    Roggeveen LF; Fleuren LM; Guo T; Thoral P; de Grooth HJ; Swart EL; Klausch TLT; van der Voort PHJ; Girbes ARJ; Bosman RJ; Elbers PWG
    Trials; 2019 Dec; 20(1):745. PubMed ID: 31852491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Size Matters: The Influence of Patient Size on Antibiotics Exposure Profiles in Critically Ill Patients on Continuous Renal Replacement Therapy.
    Jang SM; Shaw AR; Mueller BA
    Antibiotics (Basel); 2021 Nov; 10(11):. PubMed ID: 34827327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.
    Taccone FS; Laterre PF; Dugernier T; Spapen H; Delattre I; Wittebole X; De Backer D; Layeux B; Wallemacq P; Vincent JL; Jacobs F
    Crit Care; 2010; 14(4):R126. PubMed ID: 20594297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Setting the Beta-Lactam Therapeutic Range for Critically Ill Patients: Is There a Floor or Even a Ceiling?
    Barreto EF; Webb AJ; Pais GM; Rule AD; Jannetto PJ; Scheetz MH
    Crit Care Explor; 2021 Jun; 3(6):e0446. PubMed ID: 34136822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. β-lactam antibiotic concentrations during continuous renal replacement therapy.
    Beumier M; Casu GS; Hites M; Seyler L; Cotton F; Vincent JL; Jacobs F; Taccone FS
    Crit Care; 2014 May; 18(3):R105. PubMed ID: 24886826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of pharmacokinetic/pharmacodynamic and clinical outcomes with 6-hourly empiric piperacillin-tazobactam dosing in hematological malignancy patients with febrile neutropenia.
    Weber N; Jackson K; McWhinney B; Ungerer J; Kennedy G; Lipman J; Roberts JA
    J Infect Chemother; 2019 Jul; 25(7):503-508. PubMed ID: 30879981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Probability of pharmacological target attainment with flucloxacillin in Staphylococcus aureus bloodstream infection: a prospective cohort study of unbound plasma and individual MICs.
    Moser S; Rehm S; Guertler N; Hinic V; Dräger S; Bassetti S; Rentsch KM; Sendi P; Osthoff M
    J Antimicrob Chemother; 2021 Jun; 76(7):1845-1854. PubMed ID: 33860325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population Pharmacokinetics of Meropenem in Plasma and Subcutis from Patients on Extracorporeal Membrane Oxygenation Treatment.
    Hanberg P; Öbrink-Hansen K; Thorsted A; Bue M; Tøttrup M; Friberg LE; Hardlei TF; Søballe K; Gjedsted J
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29530848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic drug monitoring of β-lactam antibiotics in the ICU.
    Dhaese S; Van Vooren S; Boelens J; De Waele J
    Expert Rev Anti Infect Ther; 2020 Nov; 18(11):1155-1164. PubMed ID: 32597263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.